Trial Profile
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 03 Jul 2012 Primary endponts indentified and added as reported by European Clinical Trials Database.
- 30 Jul 2009 New trial record